Model-based optimization of controlled release formulation of levodopa for Parkinson's disease.

ABSTRACT: Levodopa is currently the standard of care treatment for Parkinson's disease, but chronic therapy has been linked to motor complications. Designing a controlled release formulation (CRF) that maintains sustained and constant blood concentrations may reduce these complications. Still, it is challenging due to levodopa's pharmacokinetic properties and the notion that it is absorbed only in the upper small intestine (i.e., exhibits an "absorption window"). We created and validated a physiologically based mathematical model to aid the development of such a formulation. Analysis of experimental results using the model revealed that levodopa is well absorbed throughout the entire small intestine (i.e., no "absorption window") and that levodopa in the stomach causes fluctuations during the first

SUBMITTER: Arav Y 

PROVIDER: S-EPMC10517026 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature